ABL Europe geht im Rahmen der GMP-Herstellung der heterologen viralen Vektor-Immuntherapie-Plattform von Hookipa Biotech eine Kooperation ein

Sorry, this entry is only available in German!

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.